Leqembi® Pen subcutaneous formulation approved in Japan

Eisai, BioArctic's partner, announced approval of a subcutaneous autoinjector formulation of Leqembi, marketed as Leqembi Pen in Japan, as a new administration route for early-stage disease treatment. The approval broadens delivery options for the Alzheimer's therapy and could support patient convenience, treatment adoption, and the commercial outlook for Eisai and BioArctic.